by Danielle Bradshaw from In The Cloud Copy Hereditary angioedema (HAE) is a rare condition in which a person has swelling beneath their skin (which can occur in any part…
According to a news release from Biospace, recent data from the KALM-2 Phase III trial highlighted how Korsuva, an injectable, is beneficial in treating severe itching associated with severe chronic…
According to a story from Hematology Advisor, the drug luspatercept (marketed as Reblozyl) recently demonstrated its ability to reduce transfusion burden in patients with beta thalassemia that depend on regular…
According to an article in the Asco Post, the FDA granted accelerated approval to Merck's KEYTRUDA®, pembrolizumab, for the treatment of metastatic small cell lung cancer (SCLC). The drug targets…
According to Fabry Disease News, patients with Fabry disease may have better outcomes when treated with enzyme replacement therapy PRX-102 over Replagal. In a one year comparison, PRX-102 seems…
According to MedPage Today, a recent study performed by researchers from the Vasculitis and Glomerulonephritis Center of Massachusetts General Hospital and Harvard Medical School found that patients with vasculitis had…
Ionis Pharmaceuticals, in a partnership with Roche, has announced that the enrollment has been completed for the third phase of GENERATION HD1, a trial intended to study the safety and…
The ME Association has recently published its latest weekly "research roundup" for the week of April 17th. This includes the latest research related to myalgic encephalomyelitis (ME), also known as…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
